期刊文献+

阿立哌唑与利培酮治疗首发女性精神分裂症患者的临床对照研究 被引量:5

A Clinical Controlled Study of Aripiprazole and Risperidone in the Treatment of First-episode Female Schizophrenia
暂未订购
导出
摘要 目的对比阿立哌唑与利培酮治疗首发女性精神分裂症患者的临床效果。方法选取2018年3月—2020年3月于该院所收治的146例首发女性精神分裂症患者为研究对象,将其随机分为利培酮组与阿立哌唑组,每组73例。分别行利培酮与阿立哌唑治疗,比较两组患者的临床疗效与不良反应的发生情况。结果两组患者的临床治疗总有效率比较(93.15%vs 90.41%),差异无统计学意义(χ^(2)=0.363,P>0.05),治疗前后两组的PANSS总分比较差异无统计学意义(P﹥0.05);阿立哌唑组患者不良反应的发生率较利培酮组更低,差异有统计学意义(P<0.05);利培酮组患者治疗后的体质量与PRL水平明显上升,且明显高于阿立哌唑组,差异有统计学意义(t=7.578、25.159,P<0.05)。结论阿立哌唑与利培酮治疗首发女性精神分裂症的临床疗效均较好,但阿立哌唑不良反应的发生较少,安全性较好,且对患者体质量与PRL的影响较小,更适合女性患者使用。 Objective To compare the clinical effects of aripiprazole and risperidone in the treatment of first-episode female schizophrenia.Methods A total of 146 first-episode female schizophrenia patients admitted to the hospital from March 2018 to March 2020 were selected as research objects and randomly divided into risperidone group and aripiprazole group,with 73 patients in each group.Risperidone and aripiprazole were used respectively to compare the clinical efficacy and the incidence of adverse reactions between the two groups.Results The total effective rate of clinical treatment between the two groups of patients was compared(93.15%vs 90.41%),and the difference was not statistically significant(χ^(2)=0.363,P>0.05).There was no statistically significant difference in the total PANSS scores of the two groups before and after treatment(P>0.05);the incidence of adverse reactions in the aripiprazole group was lower than that%in the risperidone group,and the difference was statistically significant(P<0.05);the quality and PRL level increased significantly,and were significantly higher than the aripiprazole group,the difference was statistically significant(t=7.578,25.159,P<0.05).Conclusion Both aripiprazole and risperidone have good clinical efficacy in the treatment of first-episode female schizophrenia,but aripiprazole has fewer adverse reactions,better safety,and less impact on patient body quality and PRL,so it is more suitable for female patients.
作者 王万军 WANG Wanjun(Department of Psychiatry,Mental Health Center of Rizhao City,Rizhao,Shandong Province,276800 China)
出处 《系统医学》 2021年第17期4-7,共4页 Systems Medicine
关键词 精神分裂症 阿立哌唑 利培酮 临床效果 Schizophrenia Aripiprazole Risperidone Clinical effect
  • 相关文献

参考文献14

二级参考文献112

  • 1单团结.阿立哌唑、利培酮、氯氮平对精神分裂症的治疗效果及对机体糖脂代谢的影响[J].世界临床医学,2017,11(23):72-72. 被引量:2
  • 2黄志勇.应用阿立哌唑与利培酮治疗慢性精神分裂症的疗效对比[J].当代医药论丛,2014,12(10):141-142. 被引量:4
  • 3张作记.行为医学量表手册[J].中国行为医学科学,2001,:118-119.
  • 4中华医学会精神科分会.中国精神障碍分类与诊断标准[M]:第3版[M].山东:山东科学技术出版社,2001.31-140.
  • 5Ostroff RB,Nelson JC.Risperidone augmentation of serotonin reuptake inhibitom in major depression[J].J Clin Psychiatry,1999.60:256-259.
  • 6Knopf U,Hubrich-Ungureanu P,Thome J.Paroxetine augmentation with risperidone in therapy resistant depression[J].Psychiatr Prax,2001,28:405-406.
  • 7Thase ME.What role do atypical antipsychotic drugs have in treatmentresistant depression[J].J ClinPsychiatxy,2002,63:111-113.
  • 8Sharan P,Saxena S.Treatment-resistant depression:clinical significance concept and management[J].Natl Med J India,1998,11:69-70.
  • 9Postemak MA,Zimmennma M.switching versus augrmentsfion:a prospeetive,naturalistic comparison in depressed,treatment-resistant patients[J].J Clin Psychiatry,2001,62:135-142.
  • 10Lam RW,Wan DD,Cohen NL,et al.Combining antidepressants for treatment-resistant depression:a review[J].J Clin Psychiatry,2002,63:685-693.

同被引文献63

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部